MetaVia Inc. Ordinary Shares MTVA 深 滬
等待開盤 09-23 09:30:00 美东时间
1.03
-0.010
-0.96%
華盛通- 最 高1.10
- 今 開0.97
- 成交量 46.75万股
- 最 低 0.97
- 昨 收 1.04
- 總市值 2017.68万
- 52周最高 3.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5555
- 委 比 23.25%
- 總股本 1958.91万
- 歷史最高 138900.00
- 量 比 0.02
- 振 幅 12.50%
- 歷史最低 0.5555
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket
Shares of Webtoon Entertainment Inc (NASDAQ:WBTN) rose sharply in pre-market tr...
09-16 17:41
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
HC Wainwright & Co. Assumes MetaVia at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Andrew S. Fein assumes MetaVia (NASDAQ:MTVA) with a Buy rating and announces Price Target of $12.
09-04 19:28
MetaVia Highlights Clinical Trials and Future Plans
The latest announcement is out from MetaVia ( ($MTVA) ). On August 7, 2025, Met...
08-08 05:48
MetaVia Q2 EPS $(0.26) Beats $(0.31) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 85.95 percent increase over losses of $(1.85) per share from the same
08-07 20:34
MetaVia Partners with Syntekabio for DA-1241 Research
The latest announcement is out from MetaVia ( ($MTVA) ). On August 4, 2025, Met...
08-04 21:19
Metavia Announces A Research Collaboration With Syntekabio To Identify Additional Disease Targets And Optimize The Therapeutic Profile Of DA-1241, Metavia's Novel Oral G-Protein-Coupled Receptor 119 Agonist
Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential ofMetaVia's Oral GPR119 AgonistCAMBRIDGE, Mass., Aug. 4, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a
08-04 20:34
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
CAMBRIDGE, Mass., June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an a...
06-04 20:31
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price
MetaVia ( ($MTVA) ) has shared an announcement. On May 29, 2025, MetaVia Inc. r...
05-31 05:28
